Cargando…

Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?

BACKGROUND: Fabry disease is characterized by deficient expression/activity of α-GalA with consequent lysosomal accumulation in various organs of its substrate Gb3. Despite enzyme replacement therapy, Fabry disease progresses with serious myocardial, cerebral and renal manifestations. Gb3 accumulati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ravarotto, Verdiana, Carraro, Gianni, Pagnin, Elisa, Bertoldi, Giovanni, Simioni, Francesca, Maiolino, Giuseppe, Martinato, Matteo, Landini, Linda, Davis, Paul A., Calò, Lorenzo A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160124/ https://www.ncbi.nlm.nih.gov/pubmed/30261035 http://dx.doi.org/10.1371/journal.pone.0204618

Ejemplares similares

Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?
por: Ravarotto, Verdiana, et al.
Publicado: (2018)

Rho Kinase Activity, Connexin 40, and Atrial Fibrillation: Mechanistic Insights from End-Stage Renal Disease on Dialysis Patients
por: Calò, Lorenzo A., et al.
Publicado: (2020)

The Pivotal Role of Oxidative Stress in the Pathophysiology of Cardiovascular-Renal Remodeling in Kidney Disease
por: Ravarotto, Verdiana, et al.
Publicado: (2021)

Pathomechanism of oxidative stress in cardiovascular-renal remodeling and therapeutic strategies
por: Ravarotto, Verdiana, et al.
Publicado: (2022)

The Effect of Green Tea as an Adjuvant to Enzyme Replacement Therapy on Oxidative Stress in Fabry Disease: A Pilot Study
por: Bertoldi, Giovanni, et al.
Publicado: (2022)

Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach
por: Rigato, Matteo, et al.
Publicado: (2022)

ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes
por: Calò, Lorenzo A., et al.
Publicado: (2021)

Impaired ACE2 glycosylation and protease activity lowers COVID‐19 susceptibility in Gitelman's and Bartter's syndromes
por: Bertoldi, Giovanni, et al.
Publicado: (2021)

Gitelman's and Bartter's Syndromes: From Genetics to the Molecular Basis of Hypertension and More
por: Ravarotto, Verdiana, et al.
Publicado: (2022)

ROCK (RhoA/Rho Kinase) in Cardiovascular–Renal Pathophysiology: A Review of New Advancements
por: Seccia, Teresa M., et al.
Publicado: (2020)

Oxidants and Cardiorenal Vascular Remodeling—Insights from Rare Genetic Tubulopathies: Bartter’s and Gitelman’s Syndromes
por: Sgarabotto, Luca, et al.
Publicado: (2023)

Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?
por: Bertoldi, Giovanni, et al.
Publicado: (2023)

Endothelin‐1 Drives Epithelial‐Mesenchymal Transition in Hypertensive Nephroangiosclerosis
por: Seccia, Teresa M., et al.
Publicado: (2016)

The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelman’s and Bartter’s Syndromes
por: Francini, Francesco, et al.
Publicado: (2021)

Cardiac magnetic resonance in Fabry disease
por: Lanzillo, Chiara, et al.
Publicado: (2023)

Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter’s and Gitelman’s syndrome patients
por: Calò, Lorenzo A., et al.
Publicado: (2020)

Dapaglifozin on Albuminuria in Chronic Kidney Disease Patients with FabrY Disease: The DEFY Study Design and Protocol
por: Battaglia, Yuri, et al.
Publicado: (2023)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

PLCβ1-SHP-2 complex, PLCβ1 tyrosine dephosphorylation and SHP-2 phosphatase activity: a new part of Angiotensin II signaling?
por: Calò, Lorenzo A, et al.
Publicado: (2011)

Gastrointestinal Manifestations and Low-FODMAP Protocol in a Cohort of Fabry Disease Adult Patients
por: Gugelmo, Giorgia, et al.
Publicado: (2023)

Motor involvement in Fabry disease
por: Cocozza, Sirio, et al.
Publicado: (2017)

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy
por: Iacobucci, Ilaria, et al.
Publicado: (2023)

Kidney Transplant in Fabry Disease: A Revision of the Literature
por: Capelli, Irene, et al.
Publicado: (2020)

Oxidative stress, inflammation, and peritoneal dialysis: A molecular biology approach
por: Innico, Georgie, et al.
Publicado: (2021)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

DNA methylation impact on Fabry disease
por: Di Risi, Teodolinda, et al.
Publicado: (2021)

Pathogenesis and Molecular Mechanisms of Anderson–Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies
por: Tuttolomondo, Antonino, et al.
Publicado: (2021)

Time of Anderson-Fabry Disease Detection and Cardiovascular Presentation
por: Selthofer-Relatic, K.
Publicado: (2018)

Quantitative Analysis of Conjunctival and Retinal Vessels in Fabry Disease
por: Sodi, Andrea, et al.
Publicado: (2019)

Fabry-Perot interferometers
por: Mora-Hernandez, G
Publicado: (1988)

Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy
por: Frustaci, Andrea, et al.
Publicado: (2018)

Clinical prodromes of neurodegeneration in Anderson-Fabry disease
por: Löhle, Matthias, et al.
Publicado: (2015)

The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts
por: Maiolino, Giuseppe, et al.
Publicado: (2013)

Ophthalmic Manifestations in Fabry Disease: Updated Review
por: Gambini, Gloria, et al.
Publicado: (2023)

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
por: Cammisa, Marco, et al.
Publicado: (2013)

Metabolic progression to clinical phenotype in classic Fabry disease
por: Spada, Marco, et al.
Publicado: (2017)

Pathologic substrate of gastropathy in Anderson-Fabry disease
por: Di Toro, Alessandro, et al.
Publicado: (2020)

The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field
por: Sorriento, Daniela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_moa7gbac9nhimq9j4nriqngaof